Dallas, TX -- (SBWIRE) -- 05/21/2014 -- RnRMarketResearch.com adds “PharmaPoint: Parkinson’s Disease – Current and Future Players” report to its research database.
“PharmaPoint: Parkinson’s Disease – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Parkinson’s Disease Market. The report identifies and analyses the key companies shaping and driving the global Parkinson’s Disease market. The report provides insight into the competitive Parkinson’s Disease landscape, including new companies entering the market.
Complete Report Available @ http://www.rnrmarketresearch.com/pharmapoint-parkinsons-disease-current-and-future-players-market-report.html .
Scope
- Investigation of current and future market competition for Parkinson’s Disease
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Parkinson’s Disease sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving Parkinson’s Disease market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Parkinson’s Disease market landscape? Identify, understand and capitalize
Inquiry before buying this report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=179157 .
Companies mention in this reports as follows: Merck, Roche, AbbVie, UCB, GlaxoSmithKline, Novartis, Orion, Newron, Civitas, Impax, Lundbeck
List of Tables
Table 1: Global Sales Forecasts ($m) for Parkinson's Disease, 2012-2022 14
Table 2: Parkinson's Disease Market - Drivers and Barriers, 2012-2022 16
Table 3: Key Companies in the Parkinson's Market, 2014 19
Table 4: Merck's Parkinson's Disease Portfolio Assessment, 2014 23
Table 5: Merck's PD SWOT Analysis, 2014 23
Table 6: Roche's Parkinson's Disease Portfolio Assessment, 2014 25
Table 7: Roche's PD SWOT Analysis, 2014 25
Table 8: AbbVie's Parkinson's Disease Portfolio Assessment, 2014 26
Table 9: AbbVie's PD SWOT Analysis, 2014 26
Table 10: UCB's Parkinson's Disease Portfolio Assessment, 2014 27
Table 11: UCB's PD SWOT Analysis, 2014 28
Table 12: GSK's Parkinson's Disease Portfolio Assessment, 2014 30
Table 13: GSK's PD SWOT Analysis, 2014 30
Table 14: Novartis' Parkinson's Disease Portfolio Assessment, 2014 32
Table 15: Novartis' PD SWOT Analysis, 2014 32
Table 16: Orion's Parkinson's Disease Portfolio Assessment, 2014 34
Table 17: Orion's PD SWOT Analysis, 2014 34
Table 18: Newron's Parkinson's Disease Portfolio Assessment, 2014 36
Table 19: Newron's PD SWOT Analysis, 2014 36
Table 20: Civitas' Parkinson's Disease Portfolio Assessment, 2014 37
Table 21: Civitas' PD SWOT Analysis, 2014 38
Table 22: Impax's Parkinson's Disease Portfolio Assessment, 2014 40
Table 23: Impax's PD SWOT Analysis, 2014 40
Table 24: Lundbeck's Disease/Therapy Portfolio Assessment, 2014 42
Table 25: Lundbeck's SWOT Analysis, 2014 42
List of Figures
Figure 1: Global Sales for Parkinson's Disease by Region, 2012-2022 15
Figure 2: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022 20
Order a Purchase copy this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=179157 .
Browse more reports on Parkinson Disease Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/parkinson-disease-drugs .
Connect US:
Twitter: https://twitter.com/RnRMR
Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345
Google Plus: https://plus.google.com/u/0/104156468549256253075/posts